在过去几年内,新药上市后应继续进行安全性评估,对于这一需要的认识在近几年里已不断地在提高,实际上这个过程已经达到了共识,对所有的新药,特别是那些打算广泛使用和/或长期使用的新药应受到某种形式的上市后监督。在许多情况下,全国范围内的自发报告系统被认为是充分满足需要的,但不存在有关于这种方法可行性或可信性的任何批评性评价。 In the past few years, the security assessment should continue after the new drug goes public. The awareness of this need has been continuously increasing in recent years. In fact, the process has reached a consensus that for all new drugs, especially those intended New drugs that are widely used and / or have long-term use should be subject to some form of post-marketing surveillance. In many cases, a nationwide system of spontaneous reporting is considered to be adequate to meet needs, but there are no critical evaluations of the viability or credibility of such a method.